Homocysteine-lowering therapy: a role in stroke prevention?

Lancet Neurology

Volumn 6, Issue 9, 2007, Pages 830-838

  Spence, J David ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN A1; CYANOCOBALAMIN; ENDOTHELIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HOLOTRANSCOBALAMIN; HOMOCYSTEINE; LIPID; MESNA; NITRIC OXIDE; PLACEBO; PYRIDOXINE; TRANSCOBALAMIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BRAIN INFARCTION; CLINICAL TRIAL; COGNITIVE DEFECT; CYANOCOBALAMIN DEFICIENCY; DEPRESSION; DIALYSIS; FOLIC ACID DEFICIENCY; GENETIC RISK; GENOTYPE; HEART INFARCTION; HOMOZYGOSITY; HUMAN; KIDNEY FAILURE; LIPID METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; VITAMIN SUPPLEMENTATION;

EID: 34547743420     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70219-3     Document Type: Note

References (113)

1. Mudd S., Finkelstein J., Refsum H., et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 20 (2000) 1704-1706
2. Carson N., and Neill D. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 37 (1962) 505-513
3. Gerritsen T., Vaughn J., and Waisman H. The identification of homocystine in the urine. Biochem Biophys Res Commun 9 (1962) 493-496
4. McCully K. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 56 (1969) 111-128
5. Boers G., Trijbels F., Fowler B., et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 313 (1985) 709-714
6. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 (1991) 1149-1155
7. Rozen R. Genetic modulation of homocysteinemia. Semin Thromb Hemost 26 (2000) 255-261
8. Spence J. Nutritional and metabolic aspects of stroke prevention. Adv Neurol 92 (2003) 173-178
9. Wang J., Huff A., Spence J., and Hegele R. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration. Clin Genet 65 (2004) 483-486
10. Spence J., Cordy P., Kortas C., and Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol 18 (1999) 405-410
11. Allen R., Stabler S., Savage D., and Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 7 (1993) 1344-1353
12. Nygard O., Refsum H., Ueland P., and Vollset S. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 67 (1998) 263-270
13. Desouza C., Keebler M., McNamara D., and Fonseca V. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs 62 (2002) 605-616
14. Dierkes J., and Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 5 (2005) 124-139
15. Endo N., Nishiyama K., Otsuka A., Kanouchi H., Taga M., and Oka T. Antioxidant activity of vitamin B6 delays homocysteine-induced atherosclerosis in rats. Br J Nutr 95 (2006) 1088-1093
16. Wang G., Woo C., Sung F., Siow Y., and O K. Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules. Arterioscler Thromb Vasc Biol 22 (2002) 1777-1783
17. Werstuck G., Lentz S., Dayal S., et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 107 (2001) 1263-1273
18. Hossain G., van Thienen J., Werstuck G., et al. TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 278 (2003) 30317-30327
19. Zhou J., Werstuck G., Lhotak S., et al. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. Circulation 110 (2004) 207-213
20. Austin R., Lentz S., and Werstuck G. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 11 suppl 1 (2004) S56-S64
21. Graham I., Daly L., Refsum H., et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 277 (1997) 1775-1781
22. Nygård O., Nordehaug J., Refsum H., Ueland P., Farstad M., and Vollset S. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337 (1997) 230-236
23. Toole J., Malinow M., Chambless L., et al. Lowering plasma total homocysteine to prevent recurrent stroke, myocardial infarction, and death in ischemic stroke patients: results of the Vitamin Intervention for Stroke Prevention (VISP) Randomized Trial. JAMA 291 (2004) 565-575
24. Lonn E., Yusuf S., Arnold M., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 (2006) 1567-1577
25. Bonaa K., Njolstad I., Ueland P., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
26. Casas J., Bautista L., Smeeth L., Sharma P., and Hingorani A. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 365 (2005) 224-232
27. Cronin S., Furie K., and Kelly P. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke 36 (2005) 1581-1587
28. Spence J., Barnett P., Marian A., Freeman D., Malinow M., and Hegele R. Plasma homocyst(e)ine, but not MTHFR genotype, is associated with variation in carotid plaque area. Stroke 30 (1999) 969-973
29. Lentz S. Mechanisms of thrombosis in hyperhomocysteinemia. Curr Opin Hematol 5 (1998) 343-349
30. Ebbesen L. Hyperhomocysteinemia, thrombosis and vascular biology. Cell Mol Biol 50 (2004) 917-930
31. Undas A., Brozek J., and Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 94 (2005) 907-915
32. Nishinaga M., Ozawa T., and Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 92 (1993) 1381-1386
33. Hirche F., Schroder A., Knoth B., Stangl G., and Eder K. Methionine-induced elevation of plasma homocysteine concentration is associated with an increase of plasma cholesterol in adult rats. Ann Nutr Metab 50 (2006) 139-146
34. Woo C., Siow Y., Pierce G., et al. Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors. Am J Physiol Endocrinol Metab 288 (2005) E1002-E1010
35. Li H., Lewis A., Brodsky S., Rieger R., Iden C., and Goligorsky M. Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis?. Circulation 105 (2002) 1037-1043
36. Ji C., Chan C., and Kaplowitz N. Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol 45 (2006) 717-724
37. Stamler J., Osborne J., Jaraki O., et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91 (1993) 308-318
38. Stamler J., and Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 54 (1996) 1-30
39. Liao D., Tan H., Hui R., et al. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ Res 99 (2006) 598-606
40. Klinke K., Dziewanowski K., Staniewicz A., Bukowska H., and Narusciewicz M. [Effect of vitamin therapy on homocyst(e)ine, fibrinogen and Lp(a) in dialysis patients]. Czynniki Ryzyka Suppl 4 (1998) 28
41. Mujumdar V., Hayden M., and Tyagi S. Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 183 (2000) 28-36
42. Silverman M., Tumuluri R., Davis M., Lopez G., Rosenbaum J., and Lelkes P. Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion. Arterioscler Thromb Vasc Biol 22 (2002) 587-592
43. Zhang C., Cai Y., Adachi M., et al. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 276 (2001) 35867-35874
44. Suhara T., Fukuo K., Yasuda O., et al. Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways. Hypertension 43 (2004) 1208-1213
45. Stuhlinger M., Oka R., Graf E., et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 108 (2003) 933-938
46. Sethi A., Lees D., Douthwaite J., Dawnay A., and Corder R. Homocysteine-induced endothelin-1 release is dependent on hyperglycaemia and reactive oxygen species production in bovine aortic endothelial cells. J Vasc Res 43 (2006) 175-183
47. Drunat S., Moatti N., Paul J., Cogny A., Benoit M., and Demuth K. Homocysteine-induced decrease in endothelin-1 production is initiated at the extracellular level and involves oxidative products. Eur J Biochem 268 (2001) 5287-5294
48. Zhou J., Moller J., Danielsen C., et al. Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 1470-1476
49. Wilson K., McCaw R., Leo L., et al. Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 233-240
50. Van den Berg M., Boers G., Franken D., et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 25 (1995) 176-181
51. Chambers J., McGregor A., Jean-Marie J., and Kooner J. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 351 (1998) 36-37
52. Hirsch S., Pia D., Yanez P., et al. Hyperhomocysteinemia and endothelial function in young subjects: effects of vitamin supplementation. Clin Cardiol 25 (2002) 495-501
53. Doshi S., McDowell I., Moat S., Lewis M., and Goodfellow J. Folate improves endothelial function in patients with coronary heart disease. Clin Chem Lab Med 41 (2003) 1505-1512
54. Scholze A., Rinder C., Beige J., Riezler R., Zidek W., and Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 109 (2004) 369-374
55. Wilson K., and Lentz S. Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. Semin Vasc Med 5 (2005) 163-171
56. Wilson K., McCaw R., Leo L., et al. Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 233-240
57. Werstuck G., Lentz S., Dayal S., et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 107 (2001) 1263-1273
58. Hossain G., van Thienen J., Werstuck G., et al. TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the cevelopment of atherosclerosis in hyperhomocysteinemia. J Biol Chem 278 (2003) 30317-30327
59. Zhou J., Werstuck G., Lhotak S., et al. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. Circulation 110 (2004) 207-213
60. Barbato J., Catanescu O., Murray K., DiBello P., and Jacobsen D. Targeting of metallothionein by L-homocysteine: a novel mechanism for disruption of zinc and redox homeostasis. Arterioscler Thromb Vasc Biol 27 (2007) 49-54
61. Colgan S., and Austin R. Homocysteinylation of metallothionein impairs intracellular redox homeostasis: the enemy within!. Arterioscler Thromb Vasc Biol 27 (2007) 8-11
62. Caprini J., Goldshteyn S., Glase C., and Hathaway K. Thrombophilia testing in patients with venous thrombosis. Eur J Vasc Endovasc Surg 30 (2005) 550-555
63. Ducloux D., Bresson-Vautrin C., and Chalopin J. Ocular venous occlusion and hyperhomocysteinemia. Ann Intern Med 131 (1999) 548-549
64. Eichinger S. Homocysteine, vitamin B6 and the risk of recurrent venous thromboembolism. Pathophysiol Haemost Thromb 33 (2003) 342-344
65. Hendler M., Meschengieser S., Blanco A., et al. Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects. Am J Hematol 76 (2004) 330-337
66. Lauricella A., Quintana I., and Kordich L. Effects of homocysteine thiol group on fibrin networks: another possible mechanism of harm. Thromb Res 107 (2002) 75-79
67. Lentz S., and Sadler J. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent, homocysteine. J Clin Invest 88 (1991) 1906-1916
68. Poli D., Antonucci E., Cecchi E., et al. Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 36 (2005) 2159-2163
69. Howard V., Sides E., Newman G., et al. Changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke 33 (2002) 473-478
70. Campbell N., Brant R., Stalts H., Stone J., and Mahallati H. Fluctuations in blood lipid levels during furosemide therapy: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 158 (1998) 1461-1463
71. Campbell N., Edwards A., Brant R., Jones C., and Mitchell D. Effect on lipid, complete blood count and blood proteins of a standardized preparation for drawing blood: a randomized controlled trial. Clin Invest Med 23 (2000) 350-354
72. Chambers J., Ueland P., Obeid O., Wrigley J., Refsum H., and Kooner J. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 102 (2000) 2479-2483
73. Peterson J., and Spence J. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet 351 (1998) 263
74. Hackam D., Peterson J., and Spence J. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Am J Hypertens 13 (2000) 105-110
75. Vermeulen E., van Engeland M., Visser F., et al. Effect of homocysteine-lowering vitamin treatment on electrocardiography stress tests in a randomized, placebo-controlled trial: comparison between ST-segment changes and Athen QRS-score. Int J Cardiol 93 (2004) 323-334
76. Marcucci R., Zanazzi M., Bertoni E., et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 75 (2003) 1551-1555
77. Refsum H., Nurk E., Smith A., et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr 136 suppl (2006) 1731S-1740S
78. Ortolani P., Marzocchi A., Marrozzini C., et al. Clinical relevance of homocysteine levels in patients receiving coronary stenting for unstable angina. Ital Heart J 5 (2004) 189-196
79. Schnyder G., Roffi M., Pin R., et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345 (2001) 1593-1600
80. Schnyder G., Roffi M., Flammer Y., Pin R., and Hess O. Effect of homocysteine-lowering therapy with folic acid, vitamin B(12), and vitamin B(6) on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 288 (2002) 973-979
81. Lange H., Suryapranata H., De Luca G., et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350 (2004) 2673-2681
82. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288 (2002) 2015-2022
83. Refsum H., and Smith A. Homocysteine, B vitamins, and cardiovascular disease. N Engl J Med 355 (2006) 207
84. Wald D., Law M., and Morris J. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325 (2002) 1202
85. Spence J., Howard V., Chambless L., et al. Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. Neuroepidemiology 20 (2001) 16-25
86. Rajan S., Wallace J., Brodkin K., Beresford S., Allen R., and Stabler S. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc 50 (2002) 1789-1795
87. Spence J., Bang H., Chambless L., and Stampfer M. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke 36 (2005) 2404-2409
88. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med 354 (2006) 1629-1632
89. Bazzano L., Reynolds K., Holder K., and He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 296 (2006) 2720-2726
90. Wang X., Qin X., Li H., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369 (2007) 1876-1882
91. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
92. Andres E., Loukili N., Noel E., et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 171 (2004) 251-259
93. Herzlich B., and Herbert V. Depletion of serum holotranscobalamin II. An early sign of negative vitamin B12 balance. Lab Invest 58 (1988) 332-337
94. Johnston C., and Thomas J. Holotranscobalamin II levels in plasma are related to dementia in older people. J Am Geriatr Soc 45 (1997) 779-780
95. Lindgren A., Kilander A., Bagge E., and Nexo E. Holotranscobalamin-a sensitive marker of cobalamin malabsorption. Eur J Clin Invest 29 (1999) 321-329
96. Jacques P., Selhub J., Bostom A., Wilson P., and Rosenberg I. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340 (1999) 1449-1454
97. Robertson J., Iemolo F., Stabler S., Allen R., and Spence J. Increased importance of vitamin B12 for total homocysteine and carotid plaque in the era of folate fortification of the grain supply. CMAJ 172 (2005) 1569-1573
98. Spence J. Nutrition and stroke prevention. Stroke 37 (2006) 2430-2435
99. Quinlivan E., McPartlin J., McNulty H., et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 359 (2002) 227-228
100. Geisel J., Schorr H., Bodis M., et al. The vegetarian lifestyle and DNA methylation. Clin Chem Lab Med 43 (2005) 1164-1169
101. Papadaki A., and Scott J. The impact on eating habits of temporary translocation from a mediterranean to a northern European environment. Eur J Clin Nutr 56 (2002) 455-461
102. Khanduri U., Sharma A., and Joshi A. Occult cobalamin and folate deficiency in Indians. Natl Med J India 18 (2005) 182-183
103. Carmel R., Mallidi P., Vinarskiy S., Brar S., and Frouhar Z. Hyperhomocysteinemia and cobalamin deficiency in young Asian Indians in the United States. Am J Hematol 70 (2002) 107-114
104. Olthof M., van Vliet T., Boelsma E., and Verhoef P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr 133 (2003) 4135-4138
105. Olthof M., Brink E., Katan M., and Verhoef P. Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men. Am J Clin Nutr 82 (2005) 111-117
106. Refsum H., Smith A., Ueland P., et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 50 (2004) 3-32
107. Friedman A., Bostom A., Levey A., Rosenberg I., Selhub J., and Pierratos A. Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. J Am Soc Nephrol 13 (2002) 265-268
108. House A., Eliasziw M., Urquhart B., Freeman D., and Spence J. Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial. Am J Kidney Dis 44 (2004) 689-694
109. Urquhart B., House A., Cutler M., Spence J., and Freeman D. Thiol exchange: an in vitro assay that predicts the efficacy of novel homocysteine lowering therapies. J Pharm Sci 95 (2006) 1742-1750
110. Urquhart B., Freeman D., Spence J., and House A. The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Am J Kidney Dis 49 (2007) 109-117
111. Hankey G. Is plasma homocysteine a modifiable risk factor for stroke?. Nat Clin Pract Neurol 2 (2006) 26-33
112. Furie K., and Kelly P. Homocyst(e)ine and stroke. Semin Neurol 26 (2006) 24-32
113. Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr 136 6 suppl (2006) 1726S-1730S